Litcius/Paper detail

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W. Flaig, Fábio Franke, Oscar B. Goodman, Stéphane Oudard, Thomas Steuber, Hiroyoshi Suzuki, Daphne Wu, Kesav Yeruva, Peter De Porre, Sabine Brookman‐May, Susan Li, Jinhui Li, Shibu Thomas, Katherine B. Bevans, Suneel Mundle, Sharon McCarthy, Dana E. Rathkopf

2021The Lancet Oncology106 citationsDOIOpen Access PDF

Topics & Concepts

Abiraterone acetatePrednisoneProstate cancerMedicinePlaceboAndrogen deprivation therapyInternal medicineOncologyUrologyCancerPathologyAlternative medicineProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentCancer, Lipids, and Metabolism
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study | Litcius